SPINAL CORD REPAIR WITH HUMAN UMBILICAL CORD BLOOD CELLS

Information

  • Research Project
  • 6645276
  • ApplicationId
    6645276
  • Core Project Number
    R41NS046155
  • Full Project Number
    1R41NS046155-01
  • Serial Number
    46155
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/25/2003 - 21 years ago
  • Project End Date
    6/30/2005 - 19 years ago
  • Program Officer Name
    CHIU, ARLENE Y
  • Budget Start Date
    9/25/2003 - 21 years ago
  • Budget End Date
    6/30/2005 - 19 years ago
  • Fiscal Year
    2003
  • Support Year
    1
  • Suffix
  • Award Notice Date
    9/26/2003 - 21 years ago

SPINAL CORD REPAIR WITH HUMAN UMBILICAL CORD BLOOD CELLS

DESCRIPTION (provided by applicant): With the observations that stem-like cells from outside the central nervous system (CNS) can differentiate into neurons and neural stem cells can differentiate into a variety of blood cells, it is no longer inconceivable to suggest that stem cells present in umbilical cord blood could be used to generate neural cells for transplantation treatment of neurodegenerative diseases or spinal cord injury. The ease with which the umbilical cord blood can be obtained and the cell population expanded, in conjunction with low immunogenicity of the cells could make this a preferable source of cells for transplantation. This Phase I research program proposes to identify, isolate and expand the neural progenitors obtained from umbilical cord blood and determine if these cells are capable of differentiating into mature neural cells in vitro and after transplantation in vivo. Further, once this is determined, it will be shown that these cells can produce recovery on tests of motor function in an animal model of spinal cord injury. The success of directing stem cells obtained from umbilical cord blood into a neural phenotype has important implications for the therapeutic potential of stem cells in neural transplantation in humans for spinal cord repair.

IC Name
NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
  • Activity
    R41
  • Administering IC
    NS
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    150001
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    853
  • Ed Inst. Type
  • Funding ICs
    NINDS:150001\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    SANERON CCEL THERAPEUTICS, INC.
  • Organization Department
  • Organization DUNS
    039606491
  • Organization City
    TAMPA
  • Organization State
    FL
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    33612
  • Organization District
    UNITED STATES